SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2026)
SAB Biotherapeutics (SABS) posted Cash from Investing Activities of -$65.6 million for Q1 2026, down 3747.7% on a QoQ basis from -$1.7 million in Q4 2025, and down 1505.4% year-over-year from $4.7 million in Q1 2025.
SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$65.6 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 1505.4% year-over-year to -$65.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$192.0 million (down 897.84% YoY) and the FY2025 annual result came in at -$121.7 million, down 917.42% from the prior year.
- Cash from Investing Activities was -$65.6 million for Q1 2026 at SAB Biotherapeutics, down from -$1.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $11.2 million in Q2 2024 and bottomed at -$129.9 million in Q3 2025.
- A 5-year average of -$11.9 million and a median of -$78504.0 in 2022 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 49556.96% in 2024, while the deepest fall reached 147126.32% in 2024.
- SAB Biotherapeutics' Cash from Investing Activities stood at -$117754.0 in 2022, then jumped by 42.37% to -$67864.0 in 2023, then soared by 13849.21% to $9.3 million in 2024, then tumbled by 118.29% to -$1.7 million in 2025, then sank by 3747.7% to -$65.6 million in 2026.
- Business Quant data shows SABS's Cash from Investing Activities at -$65.6 million in Q1 2026, -$1.7 million in Q4 2025, and -$129.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | -25.54 Mn |
| 10 | SAB Biotherapeutics | 188.53 Mn | 188.53 Mn | - | -65.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.65 Mn |
| Mar 31, 2026 | -65.65 Mn |
| Dec 31, 2025 | -1.71 Mn |
| Dec 31, 2025 | -1.71 Mn |
| Sep 30, 2025 | -129.87 Mn |
| Sep 30, 2025 | -129.87 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 4.67 Mn |
| Mar 31, 2025 | 4.67 Mn |
| Dec 31, 2024 | 9.33 Mn |
| Dec 31, 2024 | 9.33 Mn |
| Sep 30, 2024 | -1.15 Mn |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | 11.22 Mn |
| Jun 30, 2024 | 11.22 Mn |
| Mar 31, 2024 | -31.36 Mn |
| Mar 31, 2024 | -31.36 Mn |
| Dec 31, 2023 | -67,864.00 |
| Dec 31, 2023 | -67,864.00 |